Journal of Clinical Oncology · 1985 · 87 citations · 2 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapySolid Tumor PharmacotherapyChemotherapy For Bone SarcomaSarcoma PharmacotherapyChemotherapy For Bone TumorsClinical Trials In SarcomaHigh-dose Methotrexate TherapyHistologic Response AssessmentOsteosarcoma ChemotherapyOsteosarcoma TreatmentPartial Response Assessment
A randomized two-arm study was undertaken to determine relative tumoricidal effects of intra-arterial cis-diamminedichloroplatinum II (I/A-CDP) and high-dose methotrexate with citrovorum factor rescue (MTX-CF) in the treatment of the primary tumor in patients with osteosarcoma. Responses were evaluated by clinical, radiographic, angiographic, and pathologic parameters. Fifteen patients were randomized to receive MTX-CF and 15 to I/A-CDP. In the MTX-CF arm there were four responses (three complete responses, one partial response) whereas in the I/A CDP arm there were nine responses (seven complete responses, two partial responses). Two patients who failed MTX-CF and requested alternative treatment with I/A-CDP also responded. The total I/A-CDP response was 11/17.
2